Etiology and antimicrobial susceptibility among uropathogens causing community-acquired lower urinary tract infections: A nationwide surveillance study;Etiología y sensibilidad a los antimicrobianos de los uropatógenos causantes de la infección urinaria baja adquirida en la comunidad. Estudio nacional multicéntrico

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 23, Issue 1, 2005, Pages 4-9

  Andreua, Antonia ^a   Alós, Juan Ignacio ^b   Gobernado, Miguel ^c   Marco, Francesc ^d   De La Rosa, Manuel ^e   García Rodríguez, José Antonio ^f  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b HOSPITAL DE MÓSTOLES   (Spain)

^c HOSPITAL UNIVERSITARIO LA FE   (Spain)

^d HOSPITAL CLÍNIC   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^f HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

Antimicrobial susceptibility; Escherichia coli; Etiology; Urinary tract infection

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; CEFIXIME; CEFUROXIME; CIPROFLOXACIN; COTRIMOXAZOLE; FOSFOMYCIN; NITROFURANTOIN; PIPEMIDIC ACID; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; AGED; AGING; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM; BACTERIUM CULTURE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; COMMUNITY ACQUIRED URINARY TRACT INFECTION; ENTEROCOCCUS; ESCHERICHIA COLI; FEMALE; GEOGRAPHIC DISTRIBUTION; HUMAN; INFECTION COMPLICATION; KLEBSIELLA; LABORATORY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONHUMAN; OUTPATIENT; PROTEUS; SEX DIFFERENCE; SPAIN; URINARY TRACT INFECTION; UROPATHOGEN;

EID: 14644402409     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: 10.1157/13070401     Document Type: Article

References (26)

1. Hooton TM, Stamm WE. Diagnosis and treatment of acute uncomplicated urinary tract infection. Infec Dis Clin North Am 1997;11:551-81.
2. Gomáriz M, Viente D, Pérez E. Infecciones Urinarias no complicadas. Inf Ter Sist Nac Salud 1998;22:133-41.
3. Daza RM. Resistencia bacteriana a antimicrobianos: su importancia en la toma de decisiones en la práctica diaria. Inf Ter Sist Nac Salud 1998;22:57-67.
4. Baerheim A. Empirical treatment of uncomplicated cystitis. BMJ 2001; 323:1197-8.
5. Hooton TM. Practice guidelines for urinary tract infection in the area of managed care. Int J Antimicrob Agents 1999;11:241-5.
6. Naber KG. Treatment options for acute uncomplicated cystitis in adults. JACC 2000;46(Suppl S1):23-7.
7. Garau M, Latorre A, Alonso-Sanz M. Fosfomicina: un antibiótico infravalorado en infecciones urinarias por Escherichia coli. Enf Infecc Microbiol Clin 2001;19:462-6.
8. Villar J, Baeza JE, De Diego D, Ruiz-Poveda A, González Rodríguez JC, Barba Ferreras I, et al. Bacteriología y resistencias en las infecciones urinarias ambulatorias. Aten Primaria 1996;18:315-7.
9. García-Rodríguez JA, Trujillano Martín I, Baquero F, Cisterna R, Gobernado M, Linares F, et al. In vitro activity of fosfomycin trometamol against pathogens from urinary tract infections: A Spanish multicenter study. J Chemother 1997;9:394-402.
10. Alós JI, Balas D, Gómez JL y Grupo de estudio de Infección en atención primaria. Prevalencia de suspectibilidad a quinolonas y otros antibióticos en microorganismos aislados de bacteriurias extrahospitalarias de Madrid en 1995. Rev Clin Esp 1997;197:167-71.
11. Fuchs PC, Barry AL, Brown SD. Fosfomycin tromethamine susceptibility of outpatient urine isolates of Escherichia coli and Enterococcus faecalis from ten North American medical centres by three methods. J Antimicrob Chemother 1999;43:137-40.
12. Goettsch W, Van Pelt W, Nagelkerke N, Hendrix MG, Buiting AG, Petit PL, et al. Increasing resistance to fluorquinolones in Escherichia coli from urinary tract infections in Netherlands. J Antimicrob Chemother 2000;46: 223-8.
13. Karlowsky JA, Kelly LJ, Thornsberry C, Jones ME, Sahm DF. Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United States. Antimicrob Agents Chemother 2002;46:2540-5.
14. Kahlmenter G. An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO-SENS Project. J Antimicrob Chemother 2003;51:69-76.
15. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. Twelve informational supplement M100-S12 National Committee for Clinical Laboratory Standards, Wayne 2002.
16. Warren JW, Abrutyn E, Hebel JR, Johson JR, Schaeffer AJ, Stamm WE. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Clin Infect Dis 1999;29:745-58.
17. Naber KG, Bergman B, Bishop MC, Bjerklund-Johansen TE, Botto H, Lobel B, et al. Urinary Tract Infection (UTI) Working Group of the Health Care Office (HCO) of the European Association of Urology (EAU). EAU guidelines for the management of urinary and male genital tract infections. Eur Urol 2001;40:576-88.
18. Naber KG. Treatment options for acute uncomplicated cystitis in adults. J Antimicrob Chemother 2000;46(Suppl S1):23-7.
19. Gupta K, Hooton TM, Wobbe CL, Stamm WE. The prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in young women. Inter J Antimicrob Agents 1999;11:305-8.
20. Gupta K, Sahm DF, Mayfield D, Stamm WE. Antimicrobial resistance among uropathogens that cause community-acquired urinary tract infections in women: A nationwide analysis. Clin Infect Dis 2001;33:89-94.
21. Jones RN, Kugler KC, Pfaller MA, Winokur PL, and the SENTRY surveillance group, North America. Characteristics of pathogens causing urinary tract infections in hospitals in North America: results from the SENTRY antimicrobial surveillance program, 1997. Diagn Microbiol Infect Dis 1999; 35:55-63.
22. Fluit AC, Schmitz FJ, Verhoef J, and the European SENTRY participant group. Frecuency of isolation of pathogents from bloodstream, nosocomial pneumonia, skin and soft tissue, and urinary tract infections occurring in European patients. Eur J Clin Microbiol Infect Dis 2001;20:188-91.
23. Fluit AC, Jones ME, Schmitz FJ, Acar J, Gupta R, Verhoef J. Antimicrobial resistance among urinary tract infections (UTI) isolates in Europe: results from the SENTRY antimicrobial surveillance program, 1997. Antonie van Leeuwenhock 2000;77:147-52.
24. Pardo FJ, Moreno R, Sabater S, González F, Borrell C, Barreda A. Aspectos epidemiológicos de la resistencia de Escherichia coli a ciprofloxacino en un hospital general. Rev Esp Quimioterap 2000;13:44-50.
25. Carlone NA, Borsotto M, Cuffini AM, Savoia D. Effect of fosfomycin trometamol on bacteria adhesion in camparison with other chemotherapeutic agents. Eur Urol 1987;13(Suppl 1):86-91.
26. Ungheri D, Albini E, Belluco G. In vitro susceptibility of quinolone-resistant clinical isolates of Escherichia coli to fosfomycin trometamol. J Chemother 2002;14:237-40.